Cargando…

Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging

Non-alcoholic fatty liver disease (NAFLD) is now the commonest cause of abnormal liver function tests (LFTs) in the UK with approximately a third of the population being affected. The exact prevalence is not known, but population studies from the USA and China using magnetic resonance spectroscopy e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dyson, Jessica K, Anstee, Quentin M, McPherson, Stuart
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2014
Materias:	Liver
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4078666/ https://www.ncbi.nlm.nih.gov/pubmed/25018867 http://dx.doi.org/10.1136/flgastro-2013-100403

Ejemplares similares

Non-alcoholic fatty liver disease: a practical approach to treatment
por: Dyson, J K, et al.
Publicado: (2014)

Implementation of a care bundle improves the management of patients with non-alcoholic fatty liver disease
por: Neilson, Laura Jane, et al.
Publicado: (2021)

Republished: Non-alcoholic fatty liver disease: a practical approach to treatment
por: Dyson, J K, et al.
Publicado: (2015)

Non-alcoholic fatty liver disease is associated with higher levels of objectively measured sedentary behaviour and lower levels of physical activity than matched healthy controls
por: Hallsworth, Kate, et al.
Publicado: (2015)

Response to the NCEPOD report: development of a care bundle for patients admitted with decompensated cirrhosis—the first 24 h
por: McPherson, Stuart, et al.
Publicado: (2016)

Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis
por: McPherson, Stuart, et al.
Publicado: (2017)

Hepatitis B in pregnancy
por: Dyson, Jessica Katharine, et al.
Publicado: (2014)

Nutrigenetics-based intervention approach for adults with non-alcoholic fatty liver disease (NAFLD): study protocol for a randomised controlled feasibility trial
por: Haigh, Laura, et al.
Publicado: (2021)

Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian descent
por: De Silva, Sampath, et al.
Publicado: (2018)

Resmetirom: An Orally Administered, Smallmolecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
por: Karim, Gres, et al.
Publicado: (2023)

Nonalcoholic fatty liver disease: new treatments
por: Hardy, Timothy, et al.
Publicado: (2015)

Improved outcomes following the implementation of a decompensated cirrhosis discharge bundle
por: Smethurst, Katherine, et al.
Publicado: (2021)

Using the theoretical domains framework to identify barriers and enabling factors to implementation of guidance for the diagnosis and management of nonalcoholic fatty liver disease: a qualitative study
por: Hallsworth, Kate, et al.
Publicado: (2019)

Multiparametric magnetic resonance imaging for the assessment of non‐alcoholic fatty liver disease severity
por: Pavlides, Michael, et al.
Publicado: (2017)

Global strategy for the diagnosis and management of acute kidney injury in patients with liver cirrhosis
por: Sanchez, Lukas Otero, et al.
Publicado: (2021)

Factors associated with engagement and adherence to a low-energy diet to promote 10% weight loss in patients with clinically significant non-alcoholic fatty liver disease
por: Scragg, Jadine, et al.
Publicado: (2021)

Liver stiffness (Fibroscan®) is a predictor of all‐cause mortality in people with non‐alcoholic fatty liver disease
por: Braude, Michael, et al.
Publicado: (2022)

Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease
por: Hardy, Timothy, et al.
Publicado: (2017)

Guideline review: EASL clinical practice guidelines: drug-induced liver injury (DILI)
por: Brennan, Paul N, et al.
Publicado: (2021)

Low Levels of 25-Hydroxy Vitamin D are Independently Associated with the Risk of Bacterial Infection in Cirrhotic Patients
por: Anty, Rodolphe, et al.
Publicado: (2014)

Salford alcohol assertive outreach team: a new model for reducing alcohol-related admissions
por: Hughes, Neill R, et al.
Publicado: (2013)

The Practice of Retransplantation for Recurrent Alcohol-associated Liver Disease in the United States Is Uncommon With Acceptable Outcomes
por: Cotter, Thomas G., et al.
Publicado: (2022)

Alcohol care teams: where are we now?
por: Moriarty, Kieran John
Publicado: (2019)

Ultra‐high‐field magnetic resonance spectroscopy in non‐alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non‐alcoholic steatohepatitis and advanced fibrosis
por: Traussnigg, Stefan, et al.
Publicado: (2017)

Prescription of statins in suspected non‐alcoholic fatty liver disease and high cardiovascular risk, a population‐based study
por: van den Berg, Eline H., et al.
Publicado: (2019)

Differential fuel utilization in liver transplant recipients and its relationship with non‐alcoholic fatty liver disease
por: Siddiqui, Mohammad S., et al.
Publicado: (2022)

Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease
por: Boyle, Marie, et al.
Publicado: (2019)

Accurate non‐invasive diagnosis and staging of non‐alcoholic fatty liver disease using the urinary steroid metabolome
por: Moolla, Ahmad, et al.
Publicado: (2020)

Current treatment of non‐alcoholic fatty liver disease
por: Paternostro, Rafael, et al.
Publicado: (2022)

Advances and Emerging Therapies in the Treatment of Non-alcoholic Steatohepatitis
por: Brennan, Paul N, et al.
Publicado: (2022)

Reluctance to Accept Alcohol Treatment by Alcoholic Liver Disease Transplant Patients: A Qualitative Study
por: Heyes, Cathy M., et al.
Publicado: (2016)

Utility of Metabolomic Biomarkers to Identify Nonalcoholic Fatty Liver Disease in Liver Transplant Recipients
por: Mowry, Christopher J., et al.
Publicado: (2021)

Impact of a Mediterranean diet on hepatic and metabolic outcomes in non‐alcoholic fatty liver disease: The MEDINA randomised controlled trial
por: George, Elena S., et al.
Publicado: (2022)

Transplant Center Attitudes Toward Early Liver Transplant for Alcohol-associated Liver Disease
por: Mitchell, Jonathan, et al.
Publicado: (2023)

Staged Biliary Reconstruction After Orthotopic Liver Transplantation: A Practical Surgical Strategy for High-Acuity Adult Recipients
por: Pearson, Terra, et al.
Publicado: (2019)

The cellular pathways of liver fibrosis in non-alcoholic steatohepatitis
por: Méndez-Sánchez, Nahum, et al.
Publicado: (2020)

Network and satellite arrangements in liver disease
por: O'Grady, John G
Publicado: (2013)

Liver Transplantation Without Venovenous Bypass: Does Surgical Approach Matter?
por: Barbas, Andrew S., et al.
Publicado: (2018)

Insights Into the Experience of Liver Transplant Recipients With Alcoholic Liver Disease: A Descriptive Qualitative Study
por: Hochheimer, Martin, et al.
Publicado: (2019)

Mesenchymal iron deposition is associated with adverse long‐term outcome in non‐alcoholic fatty liver disease
por: Eder, Sebastian K., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hg0o59v2ulvq6orv6fhn19dcol